Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia

Matthew D Blunt, Stephen G Ward

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)
215 Downloads (Pure)

Abstract

PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.
Original languageEnglish
Pages (from-to)444-451
JournalCurrent Opinion in Pharmacology
Volume12
Issue number4
DOIs
Publication statusPublished - Aug 2012

Fingerprint Dive into the research topics of 'Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia'. Together they form a unique fingerprint.

Cite this